Explore the vast range of titles available.

Many research questions in fields such as personalized medicine, drug screens or systems biology depend on obtaining consistent and quantitatively accurate proteomics data from many samples. SWATH‐MS is a specific variant of data‐independent acquisition (DIA) methods and is emerging as a technology that combines deep proteome coverage capabilities with quantitative consistency and accuracy. In a SWATH‐MS measurement, all ionized peptides of a given sample that fall within a specified mass range are fragmented in a systematic and unbiased fashion using rather large precursor isolation windows. To analyse SWATH‐MS data, a strategy based on peptide‐centric scoring has been established, which typically requires prior knowledge about the chromatographic and mass spectrometric behaviour of peptides of interest in the form of spectral libraries and peptide query parameters. This tutorial provides guidelines on how to set up and plan a SWATH‐MS experiment, how to perform the mass spectrometric measurement and how to analyse SWATH‐MS data using peptide‐centric scoring. Furthermore, concepts on how to improve SWATH‐MS data acquisition, potential trade‐offs of parameter settings and alternative data analysis strategies are discussed. Graphical Abstract SWATH‐MS combines deep proteome coverage with quantitative consistency and accuracy and is often the method of choice for personalized medicine, drug screens or systems biology. This tutorial provides guidelines on how to set up SWATH‐MS experiments, perform the mass spectrometric measurements and analyse the data.

Multi‐omics studies promise the improved characterization of biological processes across molecular layers. However, methods for the unsupervised integration of the resulting heterogeneous data sets are lacking. We present Multi‐Omics Factor Analysis (MOFA), a computational method for discovering the principal sources of variation in multi‐omics data sets. MOFA infers a set of (hidden) factors that capture biological and technical sources of variability. It disentangles axes of heterogeneity that are shared across multiple modalities and those specific to individual data modalities. The learnt factors enable a variety of downstream analyses, including identification of sample subgroups, data imputation and the detection of outlier samples. We applied MOFA to a cohort of 200 patient samples of chronic lymphocytic leukaemia, profiled for somatic mutations, RNA expression, DNA methylation and ex vivo drug responses. MOFA identified major dimensions of disease heterogeneity, including immunoglobulin heavy‐chain variable region status, trisomy of chromosome 12 and previously underappreciated drivers, such as response to oxidative stress. In a second application, we used MOFA to analyse single‐cell multi‐omics data, identifying coordinated transcriptional and epigenetic changes along cell differentiation. Synopsis Multi‐Omics Factor Analysis (MOFA) is a computational framework for unsupervised discovery of the principal axes of biological and technical variation when multiple omics assays are applied to the same samples. MOFA is a broadly applicable approach for multi‐omics data integration. The inferred latent factors represent the underlying principal axes of heterogeneity across the samples. Factors can be shared by multiple data modalities or can be data‐type specific. The model flexibly handles missing values and different data types. In an application to Chronic Lymphocytic Leukaemia, MOFA discovers a low dimensional space spanned by known clinical markers and underappreciated axes of variation such as oxidative stress. In an application to multi‐omics profiles from single‐cells, MOFA recovers differentiation trajectories and identifies coordinated variation between the transcriptome and the epigenome. Graphical Abstract Multi‐Omics Factor Analysis (MOFA) is a computational framework for unsupervised discovery of the principal axes of biological and technical variation when multiple omics assays are applied to the same samples. MOFA is a broadly applicable approach for multi‐omics data integration.

Genome‐, transcriptome‐ and proteome‐wide measurements provide insights into how biological systems are regulated. However, fundamental aspects relating to which human proteins exist, where they are expressed and in which quantities are not fully understood. Therefore, we generated a quantitative proteome and transcriptome abundance atlas of 29 paired healthy human tissues from the Human Protein Atlas project representing human genes by 18,072 transcripts and 13,640 proteins including 37 without prior protein‐level evidence. The analysis revealed that hundreds of proteins, particularly in testis, could not be detected even for highly expressed mRNAs, that few proteins show tissue‐specific expression, that strong differences between mRNA and protein quantities within and across tissues exist and that protein expression is often more stable across tissues than that of transcripts. Only 238 of 9,848 amino acid variants found by exome sequencing could be confidently detected at the protein level showing that proteogenomics remains challenging, needs better computational methods and requires rigorous validation. Many uses of this resource can be envisaged including the study of gene/protein expression regulation and biomarker specificity evaluation. Synopsis Proteome and transcriptome quantification across tissues reveals which human genes exist as transcripts and proteins, where they are expressed and in which approximate quantities. Tissue‐specific protein expression is found to be a rare and quantitative rather than qualitative characteristic. The study presents the most comprehensive atlas of protein expression to date, across 29 healthy human tissues. Protein level evidence is provided for 13,640 genes and 15,257 isoforms, including 37 missing proteins. Tissue‐specific protein expression is rare and quantitative rather than qualitative characteristic. Proteogenomics is still challenging and needs rigorous validation by synthetic peptides. Graphical Abstract Proteome and transcriptome quantification across tissues reveals which human genes exist as transcripts and proteins, where they are expressed and in which approximate quantities. Tissue‐specific protein expression is found to be a rare and quantitative rather than qualitative characteristic.

An important issue for molecular biology is to establish whether transcript levels of a given gene can be used as proxies for the corresponding protein levels. Here, we have developed a targeted proteomics approach for a set of human non‐secreted proteins based on parallel reaction monitoring to measure, at steady‐state conditions, absolute protein copy numbers across human tissues and cell lines and compared these levels with the corresponding mRNA levels using transcriptomics. The study shows that the transcript and protein levels do not correlate well unless a gene‐specific RNA‐to‐protein (RTP) conversion factor independent of the tissue type is introduced, thus significantly enhancing the predictability of protein copy numbers from RNA levels. The results show that the RTP ratio varies significantly with a few hundred copies per mRNA molecule for some genes to several hundred thousands of protein copies per mRNA molecule for others. In conclusion, our data suggest that transcriptome analysis can be used as a tool to predict the protein copy numbers per cell, thus forming an attractive link between the field of genomics and proteomics. Synopsis A comparison of absolute protein copy numbers with mRNA levels across human tissues and cell lines shows that protein levels correlate well with transcript levels, if a gene‐specific and cell/tissue‐independent RNA‐to‐protein (RTP) conversion factor is introduced. A targeted proteomics approach based on spike‐in of stable isotope‐labeled protein fragments is developed to measure absolute protein copy numbers across human tissues and cell lines. Transcript and protein levels within a sample do not correlate well, unless a gene‐specific RNA‐to‐protein (RTP) factor is introduced. The RTP‐ratio varies significantly between genes, ranging from thousands to millions of protein copies per mRNA molecule, but does not vary across tissues. Transcriptome analysis can be used as a tool to predict protein copy numbers per cell, thus forming an attractive link between genomics and proteomics. Graphical Abstract A comparison of absolute protein copy numbers with mRNA levels across human tissues and cell lines shows that protein levels correlate well with transcript levels, if a gene‐specific and cell/tissue‐independent RNA‐to‐protein (RTP) conversion factor is introduced.

High‐throughput ‐omics techniques have revolutionised biology, allowing for thorough and unbiased characterisation of the molecular states of biological systems. However, cellular decision‐making is inherently a unicellular process to which “bulk” ‐omics techniques are poorly suited, as they capture ensemble averages of cell states. Recently developed single‐cell methods bridge this gap, allowing high‐throughput molecular surveys of individual cells. In this review, we cover core concepts of analysis of single‐cell gene expression data and highlight areas of developmental biology where single‐cell techniques have made important contributions. These include understanding of cell‐to‐cell heterogeneity, the tracing of differentiation pathways, quantification of gene expression from specific alleles, and the future directions of cell lineage tracing and spatial gene expression analysis. Graphical Abstract Single‐cell genomic techniques have advanced our understanding of several developmental processes. This Review summarises advances related to generating and analyzing single‐cell transcriptome data and discusses areas of developmental biology that benefited from such technologies.

Graphical Abstract

Genome‐scale metabolic models (GEMs) are widely used to calculate metabolic phenotypes. They rely on defining a set of constraints, the most common of which is that the production of metabolites and/or growth are limited by the carbon source uptake rate. However, enzyme abundances and kinetics, which act as limitations on metabolic fluxes, are not taken into account. Here, we present GECKO, a method that enhances a GEM to account for enzymes as part of reactions, thereby ensuring that each metabolic flux does not exceed its maximum capacity, equal to the product of the enzyme's abundance and turnover number. We applied GECKO to a Saccharomyces cerevisiae GEM and demonstrated that the new model could correctly describe phenotypes that the previous model could not, particularly under high enzymatic pressure conditions, such as yeast growing on different carbon sources in excess, coping with stress, or overexpressing a specific pathway. GECKO also allows to directly integrate quantitative proteomics data; by doing so, we significantly reduced flux variability of the model, in over 60% of metabolic reactions. Additionally, the model gives insight into the distribution of enzyme usage between and within metabolic pathways. The developed method and model are expected to increase the use of model‐based design in metabolic engineering. Synopsis The GECKO method takes into account enzyme abundances and kinetics to enhance genome‐scale models of metabolism (GEMs). An implementation for Saccharomyces cerevisiae gives insight into metabolism and enzyme usage. GECKO is a method that enhances a GEM with enzyme constraints, using both kinetic and omics data. The enzyme‐constrained ecYeast7 model of S. cerevisiae outperforms previous models in simulation capabilities and allows exploring enzyme usage. Directly integrating quantitative proteomic data in ecYeast7 significantly reduces the inherent flux variability of model simulations. Physiological behavior such as maximum specific growth rate, overflow metabolism and gene deletion response can be explained by a limited enzyme pool in cell. Graphical Abstract The GECKO method takes into account enzyme abundances and kinetics to enhance genome‐scale models of metabolism (GEMs). An implementation for Saccharomyces cerevisiae gives insight into metabolism and enzyme usage.

Studying protein interaction networks of all proteins in an organism (“interactomes”) remains one of the major challenges in modern biomedicine. Such information is crucial to understanding cellular pathways and developing effective therapies for the treatment of human diseases. Over the past two decades, diverse biochemical, genetic, and cell biological methods have been developed to map interactomes. In this review, we highlight basic principles of interactome mapping. Specifically, we discuss the strengths and weaknesses of individual assays, how to select a method appropriate for the problem being studied, and provide general guidelines for carrying out the necessary follow‐up analyses. In addition, we discuss computational methods to predict, map, and visualize interactomes, and provide a summary of some of the most important interactome resources. We hope that this review serves as both a useful overview of the field and a guide to help more scientists actively employ these powerful approaches in their research. Graphical Abstract A practical guide to the fundamentals of protein interaction network mapping, providing information to help researchers make effective use of proteomics approaches. A range of new and well‐established experimental and computational methods and resources are covered.

Non‐alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes most of the blood plasma proteins, liver disease may affect the plasma proteome. Plasma proteome profiling of 48 patients with and without cirrhosis or NAFLD revealed six statistically significantly changing proteins (ALDOB, APOM, LGALS3BP, PIGR, VTN, and AFM), two of which are already linked to liver disease. Polymeric immunoglobulin receptor (PIGR) was significantly elevated in both cohorts by 170% in NAFLD and 298% in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with NAFLD and cirrhosis. The prominent diabetic drug target DPP4 is an aminopeptidase like ANPEP, ENPEP, and LAP3, all of which are up‐regulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, plasma proteome profiling can identify potential biomarkers and drug targets in liver disease. Synopsis Applying Plasma Proteome Profiling to liver disease in different human cohorts associated PIGR and ALDOB and other proteins to non‐alcoholic fatty liver disease. Potential biomarkers were validated in a mouse model. Plasma proteome profiling augmented by Boxcar acquisition identified potential biomarkers of human liver diseases. PIGR and ALDOB are associated with NAFLD, among other novel proteins. DPP4, ANPEP, PIGR, APOE, and TGFBI highly correlate with AST, ALT, GGT and ALP. A mouse NAFLD model recapitulated many of the changes seen in humans. Graphical Abstract Applying Plasma Proteome Profiling to liver disease in different human cohorts associated PIGR and ALDOB and other proteins to non‐alcoholic fatty liver disease. Potential biomarkers were validated in a mouse model.

Macromolecular protein complexes carry out many of the essential functions of cells, and many genetic diseases arise from disrupting the functions of such complexes. Currently, there is great interest in defining the complete set of human protein complexes, but recent published maps lack comprehensive coverage. Here, through the synthesis of over 9,000 published mass spectrometry experiments, we present hu.MAP, the most comprehensive and accurate human protein complex map to date, containing > 4,600 total complexes, > 7,700 proteins, and > 56,000 unique interactions, including thousands of confident protein interactions not identified by the original publications. hu.MAP accurately recapitulates known complexes withheld from the learning procedure, which was optimized with the aid of a new quantitative metric ( k ‐cliques) for comparing sets of sets. The vast majority of complexes in our map are significantly enriched with literature annotations, and the map overall shows improved coverage of many disease‐associated proteins, as we describe in detail for ciliopathies. Using hu.MAP, we predicted and experimentally validated candidate ciliopathy disease genes in vivo in a model vertebrate, discovering CCDC138, WDR90, and KIAA1328 to be new cilia basal body/centriolar satellite proteins, and identifying ANKRD55 as a novel member of the intraflagellar transport machinery. By offering significant improvements to the accuracy and coverage of human protein complexes, hu.MAP ( http://proteincomplexes.org ) serves as a valuable resource for better understanding the core cellular functions of human proteins and helping to determine mechanistic foundations of human disease. Synopsis Integrating the largest‐scale mass spectrometry protein interaction datasets from a variety of human and animal cells and tissues in a machine‐learning framework generates the most comprehensive and accurate human protein complex map to date. Thousands of new interactions are identified from affinity purification/mass spectrometry datasets by applying a weighted matrix model of interactions. The resulting protein complex map strongly improves coverage of disease related genes and is examined in depth for ciliopathies. Novel centriolar satellite members are predicted and experimentally validated, and the map reveals ANKRD55 to be a new member of the intraflagellar transport machinery. Graphical Abstract Integrating the largest‐scale mass spectrometry protein interaction datasets from a variety of human and animal cells and tissues in a machine‐learning framework generates the most comprehensive and accurate human protein complex map to date.